Skip to main content

Table 1 Baseline demographics and clinical characteristics

From: Interleukin-10-producing LAG3+ regulatory T cells are associated with disease activity and abatacept treatment in rheumatoid arthritis

  RA (n = 85) Naive RA (n = 16) RA before abatacept (n = 18)
Female sex, n (%) 67 (79) 10 (63) 15 (83)
Age, years 58.9 (13.1) 55.9 (12.2) 62.7 (13.2)
Disease duration, months 139.4 (153.9) 6.7 (8.3) 187.5 (144.2)
DAS28-CRP 3.7 (1.5) 4.1 (1.6) 4.2 (1.3)
DAS28-ESR 4.4 (1.6) 4.9 (1.6) 4.9 (1.2)
CDAI 16.6 (12.1) 21.6 (14.5) 21.4 (11.7)
Rheumatoid factor, % positive 74 (87) 15 (94) 15 (83)
Anti-CCP antibody, % positive 72 (85) 13 (81) 18 (100)
Levels of CRP, mg/dl 1.81 (3.24) 3.40 (5.30) 1.54 (2.85)
Treatment naive, n (%) 16 (19) 16 (100) 0 (0)
Treatment with MTX, n (%) 41 (48) 0 (0) 10 (56)
Treatment with biologics, n (%) 19 (22) 0 (0) 5 (28)
 TNF-α inhibitor 8 (9) 0 (0) 3 (17)
 Tocilizumab 5 (6) 0 (0) 2 (11)
 Abatacept 6 (7) 0 (0) 0 (0)
  1. Abbreviations: RA Rheumatoid arthritis, DAS28 Disease Activity Score in 28 joints, CRP C-reactive protein, ESR Erythrocyte sedimentation rate, CDAI Clinical Disease Activity Index, CCP Cyclic citrullinated peptide, MTX Methotrexate, TNF Tumor necrosis factor
  2. Data are presented as mean (SD), unless otherwise specified